唑类抗真菌药对三种口服Xa因子抑制剂微剂量鸡尾酒的影响
该随机交叉试验用微剂量鸡尾酒法(25 μg利伐沙班、25 μg阿哌沙班、50 μg艾多沙班)研究六种口服唑类抗真菌药对三种Xa因子抑制剂的药物相互作用,并监测不同酶活性。结果显示酮康唑和泊沙康唑抑制作用最强,对阿哌沙班AUC比值为1.64和1.62,对艾多沙班为2.08和2.1;酮康唑使利伐沙班AUC增加2.32倍,泊沙康唑仅1.37倍。CYP3A抑制经微剂量咪达唑仑证实,酮康唑最强(8.42倍)。
要点
- 酮康唑和泊沙康唑对阿哌沙班、艾多沙班抑制最强,AUC比值约1.6–2.1。
- 酮康唑使利伐沙班AUC增加2.32倍,泊沙康唑仅1.37倍。
- 微剂量鸡尾酒法可同时研究同类不同清除途径药物的相互作用。
核心结论
- 唑类抗真菌药对三种Xa因子抑制剂的相互作用强度因 perpetrator 和 victim 不同而异,酮康唑和泊沙康唑作用最强。
研究设计与样本
- 随机交叉试验,使用含25 μg利伐沙班、25 μg阿哌沙班和50 μg艾多沙班的微剂量鸡尾酒。
- 六种口服唑类抗真菌药以治疗剂量给药24小时,微剂量鸡尾酒在唑类给药后1小时给予。
- 另用微剂量咪达唑仑监测CYP3A活性。
主要发现
- 酮康唑和泊沙康唑对阿哌沙班AUC比值分别为1.64和1.62,对艾多沙班分别为2.08和2.1。
- 酮康唑使利伐沙班AUC增加2.32倍,泊沙康唑仅增加1.37倍。
- 其他唑类抗真菌药对Xa因子抑制剂的perpetrator效应较小。
- 酮康唑对微剂量咪达唑仑的CYP3A抑制最强,AUC比值8.42。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Factor Xa inhibitors (FXaIs) are increasingly used without having sufficient drug-drug interaction data. Using a microdosed cocktail methodology could support filling the knowledge gap quickly. METHODS: In a randomised crossover trial, we investigated the drug-drug interactions between six oral azole antifungals and a microdosed FXaI cocktail containing 25 µg rivaroxaban, 25 µg apixaban, and 50 µg edoxaban. Additionally, different enzyme activities were also monitored using a microdosed cocktail approach. The six different azole antifungals were administered in therapeutic doses over a 24 h period, while the microdosed cocktails were administered 1 h after administration of the azole antifungals. RESULTS: Ketoconazole and posaconazole were the strongest perpetrators, showing similar increases as apixaban (area under the concentration-time curve ratio [AUCR] 1.64 and 1.62, respectively) and edoxaban (AUCR 2.08 and 2.1, respectively), whereas ketoconazole increased rivaroxaban 2.32-fold but only increased posaconazole 1.37-fold. All other azole antifungals showed less perpetrator effects on the FXaIs. Cytochrome P450 (CYP) 3A inhibition was confirmed using microdosed midazolam, with ketoconazole also the most potent perpetrator (8.42-fold). CONCLUSION: Drug-drug interactions for three victim drugs of the same drug class (FXaIs) with different clearance mechanisms can be studied using a microdosed cocktail approach. Using members of the azole antifungal drug class as perpetrators, multiple interactions can be studied in one trial, and a more detailed insight into the underlying interaction mechanisms is possible. CLINICAL TRIAL REGISTRATION: EudraCT number: 2017-004453-16.
引用
- Rohr BS, Foerster KI, Blank A, et al. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clin Pharmacokinet. 2021. PMID: 34273071. doi:10.1007/s40262-021-01051-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。